T-cell therapy Market by Modality (Research and Commercial), Therapy Type (CAR T-cell Therapy, T Cell Receptor-based, and Tumor Infiltrating Lymphocytes-based), and Indication (Hematologic Malignancies, Solid Tumors, and Others), and Geography: Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026870 | Pages: 100 | Industry: Pharmaceuticals | Date: Oct 2022 | Type: Global

The market crossed the US$ 6.27 billion mark in 2022 and is expected to hit US$ 27.51 billion by 2030, recording a CAGR of 20.3% during the forecast period.

Get more information on this report :

 

The T-cell therapy market has been significantly growing with the increasing incidence of cancer

The surge in demand for ideal therapeutics for cancer treatment, increase in cancer incidence, and favorable reimbursement policies in some countries are some of the major factors driving the market's growth. According to the World Health Organization (WHO), cancer was the leading cause of major deaths worldwide in 2020, accounting for nearly 10 million deaths, or nearly one in six deaths. Furthermore, according to the same source,  it is also reported that approximately 400,000 children develop cancer each year. Thus, the high incidence of cancer cases indicates the surge in demand for T-cell therapy, complementing the T-cell therapy market's growth during the forecast period.

The research segment under the modality segment is expected to pace with reduced reaction time and rapid outcomes. Further, another segment, such as CAR T-cell therapy, is expected to gain traction during the forecasted year.

Within the report, the T-cell therapy market is segmented into modality, therapy type, indication, and geography. By modality, the market is bifurcated into research and commercial. Based on therapy type, the market is segmented into CAR T-cell therapy, T Cell receptor-based, and tumor infiltrating lymphocytes-based. By indication, the market is categorized into hematologic malignancies, solid tumors, and others. Geographically, the market is sub-segmented into North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa.

T-cell Transfer Therapy is a New Technology That Empowered the Growth of Futuristic Innovations

T-cell transfer therapy is a type of immunotherapy that makes the immune cells more stronger to attack cancer. According to National Cancer Institute at the National Institutes of Health, The use of tumor-infiltrating lymphocytes (TIL) therapy has been effective for some people with melanoma and has produced promising findings in other cancers, such as cervical squamous cell carcinoma and cholangiocarcinoma. CAR T-cell therapy has also been studied to treat solid tumors, including breast and brain cancers. Thus, the rising application of T-cell therapies for cancer treatment will propel market growth.

Rising healthcare expenditure for cancer is one of the major factors accelerating the market growth.

The rising healthcare expenditure for cancer is increasing due to awareness initiatives and cancer treatment. Further, according to a report (2020) by World Health Organization (WHO), global spending on health continually rose between 2000 and 2018 and reached US$ 8.3 trillion or 10% of global GDP. Additionally, according to National Cancer Institute, in 2020, the national expenditures for cancer care was US$ 208.9 billion from US$ 190.2 in 2015. Thus, the rising expenditure on cancer care propels the demand for T-cell therapies research and application, fueling the market growth.

Recent strategic developments in T-cell therapy market

The T-cell therapy market has undergone several significant developments, and a few of these have been mentioned below:

  • In April 2022, Caribou Biosciences presents positive preclinical data for allogeneic anti-BCMA CAR-T cell therapy candidate CB-011 at the American Association for Cancer Research (AACR) Annual Meeting.
  • In January 2022, TCR2 Therapeutics Inc. and Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced that the two companies have entered into a strategic research collaboration and non-exclusive license agreement focused on the further development of a defined set of allogeneic TRuC-T cell therapies. The collaboration leverages Arbor's proprietary CRISPR gene-editing technology which is tailored to address the underlying pathology of genetic diseases, and TCR2's' first-in-class TRuC platform, which has demonstrated clinical activity in multiple treatment-refractory mesothelin-expressing solid tumor indications with its lead autologous program gavo-cel.
  • In December 2021, Novartis announced the introduction of T-Charge, the company's next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline.

The T-cell therapy market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Novartis AG; Caribou Biosciences, Inc.; Pfizer, Inc.; Sorrento Therapeutics, Inc.; Merck KGaA; Celgene Corporation; Gilead Sciences Inc.; TCR² Therapeutics; Bristol Myers Squibb; and Cartesian Therapeutics, Inc. are among the prominent players operating in the T-cell therapy market.

Target audience for the report:

  • Biotechnology Companies
  • Pharmaceutical Companies
  • Contract Research Organizations
  • Consumables Providers
  • Government Agency
  • Private Research Insitutes
  • Kits and reagent manufacturers
  • Diagnostic Laboratories

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Modality:
    • Research
    • Commercial
  • Therapy Type
    • CAR T-cell Therapy
    • T Cell Receptor-based Therapy
    • Tumor-Infiltrating Lymphocytes-based Therapy
  • Indication:
    • Hematologic Malignancies
    • Solid Tumors
    • Others

 

  • Region
    • North America
    • Europe
    • Asia Pacific (APAC)
    • South & Central America
    • Middle East & Africa

 

  • Companies profiled
    • Novartis AG
    • Caribou Biosciences, Inc.
    • Pfizer, Inc.
    • Sorrento Therapeutics, Inc.
    • Merck KGaA
    • Celgene Corporation
    • Gilead Sciences Inc.
    • TCR² Therapeutics
    • Bristol Myers Squibb
    • Cartesian Therapeutics, Inc.

The List of Companies
- Novartis AG
- Caribou Biosciences, Inc.
- Pfizer, Inc.
- Sorrento Therapeutics, Inc.
- Merck KGaA
- Celgene Corporation
- Gilead Sciences Inc.
- TCR? Therapeutics
- Bristol Myers Squibb
- Cartesian Therapeutics, Inc.

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$2000
Site License
$3000
Enterprise License
$4000